IP Library Granted Patent US 11,045,545
Granted Patent B2
US 11,045,545 · App. 16/130,787 · Granted Jun 29, 2021

IL-12 P40 monomer, monoclonal antibody against P40 homodimer and the combination of the two for autoimmune disease treatment

Inventor: Kalipada Pahan (Skokie, IL)
Assignee: Rush University Medical Center
A61K39/3955A61K38/208C07K16/24
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,045,545
App. No.
16/130,787
Granted
Jun 29, 2021
Kind
B2
Abstract

A novel approach to discover new drugs against MS and other autoimmune diseases is disclosed. The p40 family of cytokines has four members which include interleukin-12 (IL-12), the p40 monomer (p40), the p40 homodimer (p40 2 ), and the IL-23. To facilitate the studies on p40 2 and p40, neutralizing monoclonal antibodies (mAb) against mouse p40 2 and p40 were generated for the first time. MS and other autoimmune disease drug therapies including recombinant p40 and/or monoclonal antibody against p40 2 (mAb-p40 2 a3-1d) are disclosed.

Claims (8)

1. A method for treating an autoimmune disease in a mammal, the method comprising: administering a combination of a recombinant p40 monomer protein and at least one monoclonal antibody against p40 2 homodimer to the mammal for treating an autoimmune disease in the mammal, wherein the at least one monoclonal antibody against the p40 2 homodimer comprises mAb-p40 2 a3-1d.

2. The method of claim 1 , wherein the recombinant p40 monomer protein is administered in a plurality of doses.

3. The method of claim 1 , wherein the at least one monoclonal antibody against p40 2 homodimer is administered in a single dose.

4. The method of claim 1 , wherein the recombinant p40 monomer is administered in a plurality of doses and the at least one monoclonal antibody against p40 2 homodimer is administered in a single dose.

5. The method of claim 1 , wherein the administration ameliorates one or more of symptoms of the autoimmune disease, the one or more symptoms comprising demyelination, blood-brain barrier permeability, blood-spinal cord barrier permeability and combinations thereof.

6. The method of claim 1 , wherein the administration ameliorates one or more of the autoimmune diseases selected from the group consisting of multiple sclerosis, lupus, thyrioditis, rheumatoid arthritis, Sjogren's syndrome, Addison's disease and combinations thereof.

7. The method of claim 1 , wherein the at least one monoclonal antibody against p40 2 homodimer is administered in a plurality of doses.

8. The method of claim 1 , wherein the recombinant p40 monomer is administered in a plurality of doses and the at least one monoclonal antibody against p40 2 homodimer is administered in a plurality of doses.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 16, 2018
From: PAHAN, KALIPADA
To: RUSH UNIVERSITY MEDICAL CENTER
Reel/Frame 047186/0078 →
Continuity (3)
Division 14118698
Provisional Application 61487744 · May 19, 2011
Related Publication 20190008960A1 · Jan 10, 2019